Kornimate/medical-research-clean huggingface dataset:
treatment of acute hepatitis c virus infection with pegylated interferon in injection drug users

Conditions: Substance-Related Disorders; Hepatitis

Summary: injection drug use accounts for transmission of a high proportion of hepatitis c virus (hcv) infections. the purpose of this trial is to investigate the effectiveness of pegylated interferon in treating injection drug users (idus) with acute hcv.

idus are at high risk for developing hcv. pegylated interferon is a man-made form of interferon, a chemical naturally produced by the body that works to fight viruses. interferon helps to stop hcv from replicating, and helps the immune system to kill hcv. the purpose of this trial is to determine the effectiveness of pegylated interferon in idus with hcv. this trial will last 24 weeks. participants will be randomly assigned to one of two groups. group 1 will receive pegylated interferon while group 2 will receive an active control. injection with either pegylated interferon or control will occur weekly. during each injection visit, participants will be asked about adverse events, including common side effects to interferon such as injection site reactions, headache, myalgias, arthralgias, insomnia, and hair loss. at weeks 2, 4, and then every 4 weeks thereafter, participants will complete depression self-reports. laboratory assessments will occur at week 2, and then on a monthly basis for the remainder of the study. follow-up assessments will occur every 4 weeks after week 24.

Eligibility criteria:
inclusion criteria: * documented hcv antibody seroconversion within the 12 months prior to study entry * serum positive for hcv * meets hematologic, biochemical, and serologic criteria at entry visit * thyroid stimulating hormone within normal limits * hepatitis b surface antigen negative * reads at an eighth grade reading level * willing to use adequate contraception for the duration of the study * plans to remain in the study area for 12 months exclusion criteria: * positive test for hepatitis a antibodies, hepatitis b antibodies, or hiv antibodies * suspected hypersensitivity to pegylated interferon * liver disease * hemoglobinopathies * immune mediated disease * significant cardiac or pulmonary disease * uncontrolled seizure disorder * renal insufficiency with serum creatinine levels greater than 11.5 mb/ml or less than 60 mb/ml * history of thyroid disease * active gout * any medical condition requiring or likely to require steroids during the course of study * untreated severe psychiatric disorder, as determined by study psychiatrist * any condition, which in the opinion of the investigator, would preclude successful completion of the study * pregnant or breastfeeding

Keywords: hepatitis c, peg-interferon, drug abuse
glp1r polymorphisms and response to glp1

Conditions: Diabetes

Summary: glucagon-like peptide-1 (glp-1) is an important incretin hormone which acts as a powerful insulin secretagogue. defects in glp-1 synthesis and secretion are thought to be part of the pathogenesis of type 2 diabetes. furthermore glp-1 based therapy is an important part of the therapeutic armamentarium for the treatment of type 2 diabetes. the glp-1 receptor (glp1r) is the principal site of action of glp-1 and glp-1 receptor agonists like exenatide and liraglutide. the gene coding for this receptor, glp1r, is highly polymorphic and contains numerous non-synonymous single nucleotide polymorphisms (nssnps) which could potentially alter response to endogenous or exogenous glp-1 or glp-1r agonists. indeed there is some in vitro data to support this concept. we propose to utilize a hyperglycemic clamp to test the insulin secretory response to infused glp-1 in healthy volunteers to determine the effect of genetic variation in glp1r on response to glp-1.


Eligibility criteria:
inclusion criteria: * aged 18-40 * fasting glucose concentration of less than 95 mg/dl. exclusion criteria: * individuals with a bmi \ 40 kg/m\^2 * active systemic illness * medication that can alter gastric emptying, insulin secretion \& action * history of abdominal surgery (other than appendectomy or tubal ligation).

Keywords: glp-1 insulin secretion
cardiopulmonary outcomes and household air pollution trial

Conditions: Blood Pressure; Carotid Intima Media Thickness; Endothelial Function; Signs and Symptoms, Respiratory; Respiratory Function Tests

Summary: the purpose of this randomized controlled field trial is to determine whether a liquefied petroleum gas (lpg) stove and fuel distribution intervention reduces personal and kitchen exposure to household air pollutants and improves cardiopulmonary health outcomes when compared to usual cooking practices with open-fire biomass-burning stoves in adult women aged 25-64 years.

randomized, controlled field trial of an lpg stove and fuel distribution intervention compared to standard cooking practices with open-fire biomass-burning stoves in the homes of participating adult women aged 25-64 years. the aim is to determine whether provision of cleaner fuels will result in important reductions in household air pollutants and consequently in an improvement in cardiopulmonary health outcomes over a one-year period. participants randomly assigned to the intervention arm will receive a free lpg stove and fuel delivered to their homes during the one-year intervention period. participants randomly assigned to the control arm will receive a free lpg stove and vouchers that can be used to obtain free fuel for an entire year at lpg fuel distribution centers at the end of the one-year intervention period. all participants will be followed for a second year to assess patterns and impacts of sustained use (intervention arm) and initial adoption (control arm).

Eligibility criteria:
inclusion criteria: * female * full-time resident ≥6 months in current location * capable of understanding procedures * capable of providing informed consent and responding to a questionnaire * primary household cook * currently using a traditional stove as primary stove for cooking * cooking room/area separate from sleeping room/area to minimize probability of use of biomass fuel stoves for heating living space. exclusion criteria: * plans to move from the area within one year * uncontrolled hypertension * diagnosis of chronic obstructive pulmonary disease (copd) * pregnant or planning pregnancy in the next year

Keywords: air pollution liquefied petroleum gas cookstove behavioral intervention propane stove
long term special drug use investigation of mepolizumab

Conditions: Asthma

Summary: this study is a special drug use investigation program of nucala (a brand name for mepolizumab) administered subcutaneously (sc). in this study the information regarding the safety and effectiveness of long term use of nucala after subcutaneous injection will be collected from asthma subjects in daily clinical practice. the observation period per subject will be 52 weeks from the initiation of nucala treatment with follow-up investigation for 2 years after the observation period. nucala is a registered trademark of the glaxosmithkline \[gsk\] group of companies


Eligibility criteria:
inclusion criteria: * subjects receiving nucala for the first time for treatment of bronchial asthma (a refractory asthma whose symptoms are inadequately controlled despite receiving standard asthma medications) exclusion criteria: * no exclusion criteria

Keywords: exacerbation mepolizumab nucala
rheos feasibility trial

Conditions: Hypertension

Summary: the rheos feasibility trial is designed to assess safety, device performance, and protocol parameters of the cvrx rheos baroreflex therapy in patients with severe hypertension that are refractory to full drug therapy.


Eligibility criteria:
inclusion criteria: 1. be at least 21 years of age. 2. have been assessed to have bilateral carotid bifurcations located at or below c3-c4. 3. have an office cuff systolic blood pressure greater than or equal to 160 mmhg and a 24-hour ambulatory systolic blood pressure greater than or equal to 150 mmhg despite at least one month of full therapy with at least three (3) anti-hypertensive medications, of which at least one (1) must be a diuretic. 4. must be certified by the investigator hypertension specialist as compliant with taking full doses of medication. 5. have signed a cvrx approved informed consent for participation in this study. exclusion criteria: 1. have been diagnosed with: * baroreflex failure * cardiac bradyarrhythmias * chronic atrial fibrillation 2. had a heart transplant 3. have carotid atherosclerosis producing a 50% or greater reduction in linear diameter as determined by ultrasound or angiographic evaluation as determined within six months of enrollment in the trial. 4. have grade c ulcerative plaques in the carotid artery as determined by ultrasound or angiographic evaluation. 5. have prior surgery or radiation in either carotid sinus region. 6. currently have implanted electrical medical devices such as cardiac pacing, defibrillation or neurologic stimulation systems. 7. are pregnant or contemplating pregnancy during the 13-month follow-up period. 8. currently undergoing dialysis. 9. have hypertension secondary to a treatable cause. 10. have clinically significant cardiac valvular disease. 11. are unable or unwilling to fulfill the protocol medication compliance and follow-up requirements. 12. are unlikely to survive the protocol follow-up period. 13. are enrolled in another concurrent clinical trial. -
stents, drug eluting stents, and cabg- financial and clinical impact.

Conditions: Coronary Arteriosclerosis; Angina Unstable; Myocardial Infarction

Summary: options for coronary revascularization include stent implantation and coronary bypass surgery. both modalities have their unique advantages and disadvantages in terms of clinical outcomes as well as financial impact on the medical system. we wish to investigate the late results of patients undergoing coronary revascularization, the need for re-hospitalization, re-intervention, patient satisfaction as well as the financial burden on the medical system. the study will be conducted by historical prospective review of hospital records in conjunction with records of the medical insurance companies ("hmo's").

cardio-vascular disease is the second leading cause of death in the western world. two modes of treatment are currently used: coronary artery bypass graft (cabg) percutaneous interventions (pcis) i.e: balloon angioplasty and stents\[ bare metal (bms) and drug eluting (des)\]. cabg is a major operation but is considered to be safe and with good quality of life in the years to follow. the initial cost of cabg is high but usually stays low thereafter. pci is less invasive but its downfall is a high rate of restenosis hence leading to the return of angina. the initial cost is low but due to the return of symptoms the cost increases. the goal of des is to lower the rate of restenosis thus reducing the need for repeat hospitalizations and procedures. the initial cost of this stent is higher than that of the bms but still lower than that of cabg. the goal of this study is to assess and compare the average annual cost of treatment for patients with multi-vessel disease who underwent one of the following procedures: 1. cabg 2. des 3. bms the information for the study is derived from the data bases of the cardiology and cardio-thoracic surgery departments at shaarey-zedek hospital and from those of clalit health services and kupat holim meuhedet. the study design is historical prospective. the participants are insured by the above mentioned hmos and were treated during 2000-2004. the final sample's size will be decided on according to a pilot study with 15 patients from each of the treatment groups. to our knowledge no studies comparing cabg and des have yet been published. we believe that our study could become a mile stone in the process of choosing the most suitable treatment for the patient and for the health system.

Eligibility criteria:
inclusion criteria: * patients which are insured in the relevant hmo's and suffer from a multi-vessel coronary disease with occlusion of at least 70% of at least two of the main coronary vessels. exclusion criteria: * non multi- vessel disease * any additional cardiac disease 1. valvular 2. low ef (\<30%) * liver disease - according to liver enzymes * other cardiac treatment (past or immediate future) 1. active mi (24hrs before revascularization) 2. previous revascularization before beginning of follow up.

Keywords: coronary revascularization stent inmplantation coronary bypass
prevalence of problematic use of social media

Conditions: Social Networks; Addiction

Summary: in 2023, french individuals spend an average of two hours per day on social media platforms (sm), primarily facebook, tiktok, x, youtube, instagram, and snapchat. while social media offers undeniable benefits, it also raises concerns about its impact on mental health and well-being. these impacts remain poorly understood, partly due to the diversity of social media uses and motivations, which do not have uniform effects on health. for instance, studies have shown that "active" use of social media (e.g., content creation) is associated with higher well-being, whereas "passive" use (e.g., content scrolling) is linked to lower well-being. this challenge in understanding the variety of social media uses and their consequences has direct clinical implications. clinicians working in pediatrics, child psychiatry, and addiction medicine are increasingly confronted with patients struggling to manage their social media use. however, they lack clear diagnostic criteria to differentiate between normal and problematic use, as well as specific tools tailored to address potential disorders. moreover, in france, there is no existing estimate of the proportion of the general population affected by problematic social media use. this study aims to establish the prevalence of problematic use of social media in france. the investigators hypothesize that the prevalence will be close to 10%, which is the prevalence that has been found in other european countries in previous studies.


Eligibility criteria:
inclusion criteria: * aged 13 years or older. * resident in france and french-speaking. * does not object to participating in the study, and, for minors, whose parents also do not object to their participation. exclusion criteria: * unable to understand and complete the questionnaire (e.g., non-french-speaking).

Keywords: problematic use social media addiction
use of complementary and alternative medicine in children and adults with atopic dermatitis

Conditions: Atopic Dermatitis

Summary: complementary and alternative medicine are increasingly used all around the world and more specifically in chronic diseases such as atopic dermatitis. sociodemographic and disease determinants associated with their use remain unclear. moreover, most of studies involved children and little data are available for adults. the main objective of this study is to identify factors associated with complementary and alternative medicine use in children and adults suffering from atopic dermatitis. the secondary objectives are to determine the prevalence of complementary and alternative medicine use, the main forms used and their modalities of use, patients' motivations for using these therapies and sources of information. patients of all ages consulting for their atopic dermatitis at the dermatology or pediatric allergology department of nancy university hospital over a 6 months period will be asked to fill out a questionnaire about their pathology and their use of complementary and alternative medicine. this questionnaire will be collected before they leave the hospital.


Eligibility criteria:
inclusion criteria: * all patients, adults or children, without age limit; * patients visiting the dermatology or pediatric allergology department of nancy university hospital; * patients with atopic dermatitis confirmed on clinical examination by the physician; * patients with a history of atopic dermatitis or newly diagnosed patients; * patient affiliated to a social security plan or beneficiary of such a plan; * patients who understand french and are able to complete a self-administered questionnaire or have the option of assistance in completing it. exclusion criteria: * patient with at least one other dermatological pathology or non-atopic eczema (contact eczema, ...); * patient without a confirmed diagnosis of atopic dermatitis by a physician; * patient who has already completed the questionnaire during a previous consultation; * pregnant and breastfeeding women; * refusal of the patient or at least one of the parents for children; * patient placed under court protection, guardianship or curatorship; * patient deprived of liberty by a judicial or administrative decision.

Keywords: atopic dermatitis atopic eczema complementary and alternative medicine
the methylation phenotype screening and determination mode study of liver cancer prognosis related gene

Conditions: Hepatocellular Carcinoma;; Radical Hepatic Resection;

Summary: recurrence and metastasis are the main factors affecting the prognosis of liver cancer after curative resection. establishing an effective prognostic evaluation method is able to not only assess patients' prognosis but also guide the treatment. at the same time, it helps us to gain knowledge of the mechanism underlying recurrence and metastasis of liver cancer and to provide the basis for the search for new effective intervention method. in order to establish an effective prognostic evaluation method, we select liver cancer patients undergoing curative resection in our hospital. we plan to employ various technologies such as gene chip, methylation chip and flow cytometry to carry out comprehensive researches on liver cancer cell genetics, epigenetics, stem cells and tumor microenvironment changes. by analyzing clinical information including pathological features, patients' response to treatment, relapse, metastasis and survival, we aim to obtain the important factors affecting liver cancer prognosis, survival, recurrence and metastasis in order to be able to find and establish the effective prognostic evaluation method.

recurrence and metastasis are the main factors affecting the prognosis of liver cancer after curative resection. establishing an effective prognostic evaluation method is able to not only assess patients' prognosis but also guide the treatment. at the same time, it helps us to gain knowledge of the mechanism underlying recurrence and metastasis of liver cancer and to provide the basis for the search for new effective intervention method. in order to establish an effective prognostic evaluation method, we select liver cancer patients undergoing curative resection in our hospital. we plan to employ various technologies such as gene chip, methylation chip and flow cytometry to carry out comprehensive researches on liver cancer cell genetics, epigenetics, stem cells and tumor microenvironment changes. by analyzing clinical information including pathological features, patients' response to treatment, relapse, metastasis and survival, we aim to obtain the important factors affecting liver cancer prognosis, survival, recurrence and metastasis in order to be able to find and establish the effective prognostic evaluation method.

Eligibility criteria:
inclusion criteria: 1. patients with radical hepatectomy in eastern hepatobiliary surgery hospital; 2. hepatocellular carcinoma confirmed pathologically; 3. the liver function is child-pugh a, as well as the child-pugh b achieved to a after treatment; 4. the hai score of cirrhosis \<12 exclusion criteria: 1. patients with apparent cardiac, pulmonary, cerebric and renal dysfunction,which may affect the treatment of liver cancer. 2. patients with other diseases which may affect the treatment mentioned here. 3. patients with medical history of other malignant tumors.
targeting vascular inflammation in patients with community-acquired pneumonia

Conditions: Inflammation; Community Acquired Pneumonia (CAP); Inflammation Plaque, Atherosclerotic

Summary: the goal of this clinical trial is to learn if icosapent ethyl (vascepa) works to lessen the amount of inflammation in adults diagnosed with community-acquired pneumonia (cap). the main question it aims to answer is: what is the effect of taking vascepa on inflammation in the arteries in patients with cap? researchers will compare the drug vascepa to a placebo (a look-alike submstance that contains no drug) to see if vascepa works to reduce inflammation in patients with cap. participants wil: * take vacscepa or a placebo twice a day for 6 months * visit the clinic 3 times (baseline, 30 days, and 6 months) for checkups and tests

tin cap is a multi centre, prospective, randomized, double-blind, placebo-controlled clinical trial to evaluate the use of icosapent ethyl (vascepa) on vascular inflammation in patients with cap using fdg-pet/ct imaging and measurement of circulating biomarkers. the current proposal uses a randomized design to: 1. measure the effect of icosapent ethyl vs. placebo on reducing arterial inflammation over a 6-month treatment period, with primary analysis at 6-months; 2. the correlation between imaging and blood biomarkers over time relative to the drug response.

Eligibility criteria:
inclusion criteria: patients who have: 1. hospitalization with cap (defined as pulmonary infiltration using chest imaging, in addition to other clinical symptoms including fever, cough, and sputum) 2. age \> 18 years; 3. given informed consent. exclusion criteria: patients who have: 1. history of cancer within the last 3 years (other than a successfully treated cutaneous squamous cell or basal cell carcinoma or localized carcinoma in situ of the cervix). 2. active inflammatory conditions (e.g. rheumatoid arthritis, chronic inflammatory bowel disease, sle, systemic anti-inflammatory therapy (e.g. prednisone, methotrexate)); 3. pregnancy (all women of child bearing potential will have a negative bhcg test; 4. breastfeeding; 5. women of childbearing potential who refuse to use two forms of contraception (this includes at least one form of highly effective and one effective method of contraception) throughout the study or men capable of fathering a child who refuse to use contraception. 6. allergies to icosapent ethyl 7. allergies to fish or shellfish 8. glomerular filtration rate (gfr) \<50 ml/min/1.72m2 (excluded from cta portion) 9. unable to give informed consent; exclusion for cta portion of the protocol: patients with dye allergy will not undergo cta but will have pet/ct

Keywords: community-acquired infection plaque, atherosclerotic inflammation eicosapentaenoic acid
microcirculation & asics

Conditions: Physiological Conditions

Summary: pressure ulcers are a common and costly problem. advancing the understanding regarding the basic pathophysiological mechanisms mediating the development of pressure ulcers will allow for better delineation of populations at risk. healthy skin is protected from pressure-induced ischemic damage because of the presence of pressure-induced vasodilation (piv). in contrast, in absence of piv, such as in diabetic patients or older subjects with sensory neuropathy, the skin is exposed to severe cutaneous ischemia, which could lead to pressure ulcer formation. since acid sensing ion channels (asics) appear to be involved in the cutaneous mechanosensitivity, the investigators hypothesized that piv could be altered by treatments that block asics.


Eligibility criteria:
inclusion criteria: * healthy adult males or females aged between 18 and 40 years of age exclusion criteria: * no consent, diabetes, neuropathy.

Keywords: skin, microcirculation; asic, pressure ulcer